SNGX - Soligenix Inc. logo

Soligenix Inc.

SNGX

Soligenix Inc. develops biopharmaceutical products for rare diseases, focusing on cutaneous T-cell lymphoma and inflammatory conditions. It also creates vaccines for biodefense and infectious diseases, such as ricin exposure and COVID-19.

โš•๏ธ Healthcare NASDAQ Listed 1987 $ USD
$1,000 invested 30 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth7.59%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.7
Net Growth18.42%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-215.55%
Net Trend30%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency
20 Years
Score2.3
Net Growth-25.44%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev Trend45%
Revenue Consistency
30 Years
Scoreโ€”
Net Growth-422.42%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev Trend48%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-6x
Net Trend39%
Net Income Consistency
Rev Growthโ€”
Rev Trend48%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Soligenix Inc. has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • SNGX

2014: 90.4% ยท 2021: 98.4% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 0.36โ€”
1 Year2025-09-29
$ 1.11-67.12%
5 Years2021-09-29
$ 252.00-99.86%
10 Years2016-09-29
$ 1.87K-99.98%
20 Years2006-09-29
$ 12.96K-100.00%
30 Years1996-09-27
$ 945K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 10M$ 9M
2025$ 0.00-$ 11M$ 7M
2024$ 119.37K-$ 8M$ 7M
2023$ 839.36K-$ 6M$ 8M
2022$ 250K-$ 13M$ 13M
2021$ 33.35K-$ 12M$ 26M
2020$ 1M-$ 17M$ 18M
2019$ 3M-$ 9M$ 5M
2018$ 5M-$ 8M$ 8M
2017$ 5M-$ 7M$ 7M
2016$ 10M-$ 3M$ 8M
2015$ 8M-$ 7M$ 4M
2014$ 7M-$ 6M$ 5M
2013$ 3M-$ 10M$ 5M
2012$ 3M-$ 4M$ 3M
2011$ 7M-$ 2M$ 5M
2010$ 1M-$ 7M$ 7M
2009$ 2M-$ 6M$ 7M
2008$ 2M-$ 3M$ 1M
2007$ 1M-$ 6M$ 2M
2006$ 2M-$ 8M$ 119.64K
2005$ 3M-$ 4M$ 821.7K
2004$ 997.48K-$ 5M$ 2M
2003$ 83.82K-$ 5M$ 4M
2002-$ 4M$ 4M
2001-$ 14M$ 9M
2000-$ 4M$ 12M
1999-$ 7M$ 8M
1998-$ 21M$ 12M
1997-$ 3M$ 15M
1996-$ 1M
1995-$ 1M$ 1M
SNGX - Soligenix Inc. logo

Soligenix Inc. fundamental performance

Between 2020 and 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 17M to -$ 11M. Revenue increased in 2 of those 5 years; net income in 2.

Between 2005 and 2025, revenue declined from $ 3M to $ 0.00 and net income went from -$ 4M to -$ 11M. Revenue increased in 9 of those 20 years; net income in 8.

Soligenix Inc. currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.

Membership

Continue SNGXโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies